ATXS

ATXS

USD

Astria Therapeutics Inc. Common Stock

$12.250+0.120 (0.989%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$12.130

最高价

$12.390

最低价

$12.110

成交量

1.43M

公司基本面

市值

691.3M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

1.58M

交易所

NGM

货币

USD

52周价格范围

最低价 $3.555当前价 $12.250最高价 $12.715

相关新闻

BusinessWire

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the

查看更多
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
PR Newswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

查看更多
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders
Analyst Upgrades

JMP Securities Downgrades Astria Therapeutics to Market Perform

JMP Securities analyst Jonathan Wolleben downgrades Astria Therapeutics from Market Outperform to Market Perform.

查看更多
JMP Securities Downgrades Astria Therapeutics to Market Perform
PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

查看更多
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)
Analyst Upgrades

Jefferies Downgrades Astria Therapeutics to Hold, Lowers Price Target to $13

Jefferies analyst Eun Yang downgrades Astria Therapeutics from Buy to Hold and lowers the price target from $30 to $13.

查看更多
Jefferies Downgrades Astria Therapeutics to Hold, Lowers Price Target to $13
PR Newswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS, PCH, RYN on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PR Newswire

Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

The Ademi Firm is investigating Astria (NASDAQ: ATXS) for possible breaches of fiduciary duty and other violations of law in its transaction with...